Clinical Trial: Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer

U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07895355) titled 'Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer' on Oct. 12.

Brief Summary: RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy

Intervention: DRUG: RC148 plus Telisotuzumab adizutecan

Dose 1/ Dose 1

DRUG: RC148 plus Telisotuzumab adizutecan

Dose 2/ Dose 1

DRUG: RC148 plus Telisotuzumab ad...